Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

NCT00697567 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Prophylaxis Herpes Simplex

Interventions

BIOLOGICAL: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
BIOLOGICAL: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant

Sponsor

GlaxoSmithKline